Contact this trialFirst, we need to learn more about you.
Nucleoside Metabolic Inhibitor
Venetoclax + Azacitidine for Acute Myeloid Leukemia
Recruiting1 awardPhase 3
Brewer, Maine
This trial is testing a new combination treatment for acute myeloid leukemia (AML), a cancer of the blood and bone marrow. The treatment consists of the experimental drug venetoclax, which kills cancer cells by blocking a protein that allows them to stay alive, combined with azacitidine. The study will enroll approximately 400 participants globally and will compare the efficacy of the new combination treatment to azacitidine alone.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service